Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16355776 | 0.88 | LMNA (0.50) | ALDH1A1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL5190209 | 0.87 | LMNA (0.59) | ALDH1A1SMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL734928 | 0.86 | ATM (0.55) | ALDH1A1KMT2ASMN1; SMN2KDM4EATM | |
| SCHEMBL27412143 | 0.85 | ALDH1A1 (0.41) | ALDH1A1NR1H4EPHX2KMT2AMAPT | |
| SCHEMBL557679 | 0.85 | ALDH1A1 (0.49) | ALDH1A1NR1H4EPHX2KMT2ASMN1; SMN2 | |
| SCHEMBL13662612 | 0.84 | ATM (0.44) | KMT2ASMN1; SMN2LMNAHPGDMAPT | |
| SCHEMBL8421187 | 0.84 | VSIR (0.44) | LMNAHPGDMAPTATM | |
| SCHEMBL14205020 | 0.84 | KMT2A (0.46) | ALDH1A1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL15876277 | 0.84 | MTNR1A (0.42) | SMN1; SMN2LMNAHPGDMAPTATM | |
| Hydrochloric Acid SCHEMBL6433307 | 0.84 | ATM (0.53) | ALDH1A1KMT2ASMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879853-B2 | tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| EP-1763526-B1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | EP | disclosed |
| EP-1313703-B1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1763526-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Altana Pharma AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000589-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-01-05 | — | — | WO | disclosed |
| EP-1313703-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-6407235-B1 | A NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR-SUBTYPE SELECTIVE BLOCKERS; PRODRUGS HAVE IMPROVED SOLUBILITY AND ARE HYDROLYZED IN VIVO; FOR EXAMPLE, THE 4-AMINOMETHYL-BENZOIC ACID ESTER OF THE PHENOL, OR THE PHOSPHATE ESTER | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | EVOTEC INTERNATIONAL GMBH (DE) | 2002-04-04 | — | — | US | disclosed |
| WO-2002016321-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | HAO2, CYP2B6, CBR1 | ALDH1A1 149/4885NR1H4 350/4885EPHX2 45/4885 |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | ALDH1A1 2113/4885NR1H4 2961/4885EPHX2 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.